| Name | Title | Contact Details |
|---|
Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MEM SLOAN KETTERING CANCER C is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients` lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek. Our Vision To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
A&A Phamachem Inc. is a Nepean, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.